Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2012

View Archived Issues

New auristatin derivatives for cancer prepared at Bayer Schering Pharma

Preclinical study identifies new Wnt signaling inhibitors that regulate cardiogenesis

Novel approach leads to discovery of NME that prevents tumor invasion

Silence Therapeutics and miRagen to collaborate on microRNA-based therapeutics

KAI Pharmaceuticals begins recruitment in second phase II study of KAI-4169

Ongoing phase I/II trial assesses combinations of letrozole with SAR-245408 and SAR-245409

Phase I/II data presented on SAR-245408-based combination regimens in metastatic breast cancer

New Evestra progesterone receptor inhibitor shows potential as breast cancer therapy

AstraZeneca patents new protein kinase inhibitors

Novel estrogen receptor-alpha modulators prepared by Aragon Pharmaceuticals

AstraZeneca and Pulmagen Therapeutics patent novel compounds for respiratory disorders

Clinical study of intranasally administered HIV vaccine fully enrolled

Scientists at Merck & Co. prepare new PRCP inhibitors

MDA provides financial support for preclinical work on TVN-102

New MAP kinase p38 inhibitors synthesized

Ista Pharmaceuticals begins phase II trial of combination nasal spray for seasonal allergic rhinitis

MHRA accepts Shire's MAA for once-daily ADHD therapy for review

Novel serine/threonine-protein kinase PAK inhibitors designed

Pfizer begins phase I study of PF-05280602

GSK and Theravance report data from phase III Relovair studies

Civitas Therapeutics reports results from phase I CVT-301 trial

Phase II trial of diabetes vaccine reaches full enrollment

Novavax provides update on joint venture in India

Astellas and Theravance terminate license agreement

Alnylam files ALN-TTR02 CTA with MHRA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...